EGFR and non-small cell lung carcinoma: Among them, epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have become the first-line therapy for patients with advanced NSCLC harboring EGFR-TKI-sensitive mutations, considering their higher response rate and lower toxicity compared with conventional chemotherapy (Maemondo et al., 2010; Lee et al., 2017; Ramalingam et al., 2020).